Sumitomo Mitsui Trust Group
NRIX icon

Sumitomo Mitsui Trust Group’s Nurix Therapeutics NRIX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.3M Sell
1,181,146
-109,408
-8% -$1.81M 0.01% 627
2025
Q4 		$24.5M Sell
1,290,554
-266,925
-17% -$3.83M 0.01% 615
2025
Q3 		$14.4M Buy
1,557,479
+165,841
+12% +$1.72M 0.01% 660
2025
Q2 		$15.9M Buy
1,391,638
+635,668
+84% +$6.87M 0.01% 644
2025
Q1 		$8.98M Sell
755,970
-33,252
-4% -$556K 0.01% 698
2024
Q4 		$14.9M Buy
789,222
+235,971
+43% +$5.41M 0.01% 679
2024
Q3 		$12.4M Buy
+553,251
New +$12.5M 0.01% 690

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group's NRIX Position: Q1 2026 in Review

Sumitomo Mitsui Trust Group reduced its Nurix Therapeutics (NRIX) stake by 8.5% in Q1 2026, selling an estimated $1.81M and leaving 1,181,146 shares worth $18.3M. The position accounts for 0.01% of the portfolio, ranked #627.

Sumitomo Mitsui Trust Group first reported a position in NRIX in Q3 2024 and has held it in 7 quarters since. The position peaked at $24.5M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Sumitomo Mitsui Trust Group held 1,181,146 shares of Nurix Therapeutics worth $18.3M as of Q1 2026.
  • Sumitomo Mitsui Trust Group sold 109,408 Nurix Therapeutics shares in Q1 2026, an estimated $1.81M.
  • Nurix Therapeutics made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q1 2026, its #627 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Sumitomo Mitsui Trust Group's Nurix Therapeutics position peaked at $24.5M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2026, filed 30 Apr 2026.